Research & Development
The discovery and development of innovative new medicines is the foundation of our business at Astellas.
We invest 16% of our global annual sales in R&D.
At our Drug Discovery Research Centre in Japan, scientists strive to discover new chemical compounds with the potential to influence the biological processes that cause diseases. The most promising new candidates are then investigated in rigorous clinical trial programmes to assess their efficacy and safety at state-of-the-art research centres (overseen by our Drug Development Headquarters in Illinois, USA).
Strategic acquisitions of companies like Ocata (Astellas Institute for Regenerative Medicine), Ogeda and Ganymed have augmented our in-house expertise. Additionally, our approach to R&D has also seen recent collaborations with a wide range of renowned academic and biotechnology organisations with complementary capabilities.
The next phase of our ongoing R&D investment strategy includes increased focused on oncology, as well as innovative technologies such as regenerative medicine.